The Korean Journal of Medicine

  • 제99권5호
  • /
  • Pages.253-262
  • /
  • 2024
  • /
  • 1738-9364(pISSN)
  • /
  • 2289-0769(eISSN)
대한내과학회 (The Korean Association of Internal Medicine)
권호 표지
DOI QR코드

DOI QR Code

작은 관상동맥질환 환자에서 약물 용출 풍선과 약물 용출 스텐트 시술 후 임상 경과의 비교

Comparison of Clinical Outcomes between Drug-Eluting Balloons and Drug-Eluting Stents in Patients with Small Coronary Artery Disease

  • 김만수 (전남대학교병원 심혈관센터) ;
  • 박성호 (전남대학교병원 심혈관센터) ;
  • 오석 (전남대학교병원 심혈관센터) ;
  • 현대용 (전남대학교병원 심혈관센터) ;
  • 이승헌 (전남대학교병원 심혈관센터) ;
  • 임용환 (전남대학교병원 심혈관센터) ;
  • 안준호 (전남대학교병원 심혈관센터) ;
  • 조경훈 (전남대학교병원 심혈관센터) ;
  • 김민철 (전남대학교병원 심혈관센터) ;
  • 심두선 (전남대학교병원 심혈관센터) ;
  • 홍영준 (전남대학교병원 심혈관센터) ;
  • 김주한 (전남대학교병원 심혈관센터) ;
  • 안영근 (전남대학교병원 심혈관센터) ;
  • 정명호 (전남대학교병원 심혈관센터)
  • Man Su Kim (Cardiovascular Center, Chonnam National University Hospital) ;
  • Seong Ho Park (Cardiovascular Center, Chonnam National University Hospital) ;
  • Seok Oh (Cardiovascular Center, Chonnam National University Hospital) ;
  • Dae Yong Hyun (Cardiovascular Center, Chonnam National University Hospital) ;
  • Seung Hun Lee (Cardiovascular Center, Chonnam National University Hospital) ;
  • Yong Hwan Lim (Cardiovascular Center, Chonnam National University Hospital) ;
  • Jun Ho Ahn (Cardiovascular Center, Chonnam National University Hospital) ;
  • Kyung Hoon Cho (Cardiovascular Center, Chonnam National University Hospital) ;
  • Min Chul Kim (Cardiovascular Center, Chonnam National University Hospital) ;
  • Doo Sun Sim (Cardiovascular Center, Chonnam National University Hospital) ;
  • Young Joon Hong (Cardiovascular Center, Chonnam National University Hospital) ;
  • Ju Han Kim (Cardiovascular Center, Chonnam National University Hospital) ;
  • Youngkeun Ahn (Cardiovascular Center, Chonnam National University Hospital) ;
  • Myung Ho Jeong (Cardiovascular Center, Chonnam National University Hospital)
  • 투고 : 2024.01.05
  • 심사 : 2024.07.09
  • 발행 : 2024.10.01
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

목적: 약물 용출 풍선(drug-eluting balloon, DEB)은 작은 관상동맥 질환 환자를 위한 새로운 치료 전략이나 약물 용출스텐트(drug-eluting stent, DES)에 비하여 임상적 효과에 관한 연구가 더 많이 필요한 실정이다. 본 연구에서는 작은 혈관 병변을 동반한 환자를 대상으로 DEB와 DES 시술 후 1년간의 임상 효과를 비교 분석하였다. 방법: 2021년 1월부터 2022년 9월까지 2.75 mm 미만의 작은 관상동맥 병변을 가진 492명의 환자(67.9 ± 11.0세; 남자 339명)를 시술 후 1년간 추적 관찰하여 주요 심장 사건(major adverse cardiac events, MACE)을 분석하였다. MACE는 모든 원인 사망, 표적 혈관 재관류(target vessel revascularization, TVR), 표적 병변 재관류(target lesion revascularization, TLR), 스텐트 혈전증(stent thrombosis, ST), 심근경색증(myocardial infarction, MI)으로 하였다. 대상 환자 중 DEB를 사용한 환자를 I군(104명; 67.2 ± 10.7세; 남자 83명), DES를 사용한 환자를 II군(388명; 68.0 ± 11.1세; 남자 254명)으로 분류하여 비교 분석을 하였고 역처리 확률 가중법(inverse probability of treatment weighting, IPTW)을 실시하여 I군 269명과 II군 280명을 추가 분석하였다. 결과: 위험 요인 중 흡연이 I군이 II군보다 많았다(23명 [22.1%] vs. 36명[9.3%]; p < 0.001). 시술 도자의 길이는 I군이 II군보다 짧았고(22.4 ± 5.9 vs. 27.4 ± 9.3 mm; p < 0.001) 시술 도자의 직경도 I군이 II군보다 작았으며(2.4 ± 0.1 vs. 2.6 ± 0.1 mm; p < 0.001) 좌심실 구혈률은 I군이 II군보다 낮았다(53.8% ± 12.6% vs. 58.6% ± 11.9%; p < 0.001). IPTW 시행 후에는 I군과 II군의 좌심실 구혈률의 차이는 보이지 않았고 시술 도자의 길이는 I군이 II군보다 짧았으며(21.9 ± 5.9 vs. 26.9 ± 9.2 mm; p < 0.001) 시술 도자의 직경도 I군이 II군보다 작았다(2.5 ± 0.2 vs. 2.6 ± 0.1 mm; p < 0.001). 일 년간 추적 관찰 시에 모든 원인 사망(0.4% vs. 1.1%; p = 0.450), TLR (2.4% vs. 1.1%; p = 0.444), TVR (2.2% vs. 4.9%; p = 0.333) 및 ST (0.0% vs. 0.4%; p = 0.330)는 I군과 II군에서 차이가 없었으며 MACE 발생률도 I군과 II군 간의 유의한 차이를 보이지 않았다(5.0% vs. 7.5%; p = 0.513). 결론: 작은 관상동맥 질환의 치료에서 DEB의 사용은 DES와 비교하여 1년간 관찰한 임상 경과에 유의한 차이가 없었다.

Background/Aims: Drug-eluting balloons (DEBs) represent a novel therapeutic approach for patients with small coronary artery disease. However, further studies are needed to compare the clinical efficacy of DEBs versus drug-eluting stents (DESs). Methods: In total, 492 patients (age, 67.9 ± 11.0 years; 339 men) with small coronary artery lesions (diameter < 2.75 mm) were randomly assigned to group I (DEB) (n = 104; age, 67.2 ± 10.7 years; 83 men) and group II (DES) (n = 388; age, 68.0 ± 11.1 years; 254 men). For inverse probability of treatment weighting (IPTW) analysis, the study population was stratified into groups I (n = 269) and II (n = 280). We compared the incidences of major adverse cardiac events (MACE) between the two groups during 12 months of clinical follow-up. Results: Group I had shorter device lengths (22.4 ± 5.8 mm) compared with group II (27.4 ± 9.3 mm; p < 0.001). Additionally, devices in group I were smaller in diameter (2.4 ± 0.1 mm) compared with those in group II (2.6 ± 0.1 mm; p < 0.001). Left ventricular ejection fraction (LVEF) was lower in group I (53.8% ± 12.6%) than in group II (58.6% ± 11.9%; p < 0.001). After IPTW, no significant differences in LVEF were observed between groups I and II. During 12 months of follow-up, the incidence of total MACE did not differ between the two groups. Conclusions: No significant differences were observed in clinical efficacy between DEB and DES for the treatment of small coronary artery disease. Therefore, DEB can be considered a viable alternative to DES in patients with small coronary artery disease.

키워드

과제정보

This work was supported in part, by the Chonnam National University Hospital Research Fund.

참고문헌

  1. Yerasi C, Case BC, Forrestal BJ, et al. Drug-coated balloon for de novo coronary artery disease: JACC state-of-the-art review. J Am Coll Cardiol 2020;75:1061-1073.
  2. Wong YTA, Kang DY, Lee JB, et al. Comparison of drug-eluting stents and drug-coated balloon for the treatment of drug-eluting coronary stent restenosis: a randomized RESTORE trial. Am Heart J 2018;197:35-42.
  3. Unverdorben M, Vallbracht C, Cremers B, et al. Paclitaxel-coated balloon catheter versus paclitaxel-coated stent for the treatment of coronary in-stent restenosis. Circulation 2009; 119:2986-2994.
  4. Jeger RV, Eccleshall S, Wan Ahmad WA, et al. Drug-coated balloons for coronary artery disease: third report of the International DCB Consensus Group. JACC Cardiovasc Interv 2020;13:1391-1402.
  5. Stone GW, Ellis SG, O'Shaughnessy CD, et al. Paclitaxel-eluting stents vs vascular brachytherapy for in-stent restenosis within bare-metal stents: the TAXUS V ISR randomized trial. JAMA 2006;295:1253-1263.
  6. Cortese B, Di Palma G, Guimaraes MG, et al. Drug-coated balloon versus drug-eluting stent for small coronary vessel disease: PICCOLETO II randomized clinical trial. JACC Cardiovasc Interv 2020;13:2840-2849.
  7. Song CX, Zhou C, Hou W, et al. Drug-eluting balloons versus drug-eluting stents for small vessel coronary artery disease: a meta-analysis. Coron Artery Dis 2020;31:199-205.
  8. Cuculi F, Bossard M, Zasada W, et al. Performing percutaneous coronary interventions with predilatation using non-compliant balloons at high-pressure versus conventional semi-compliant balloons: insights from two randomised studies using optical coherence tomography. Open Heart 2020;7:e001204.
  9. Byrne RA, Neumann FJ, Mehilli J, et al. Paclitaxel-eluting balloons, paclitaxel-eluting stents, and balloon angioplasty in patients with restenosis after implantation of a drug-eluting stent (ISAR-DESIRE 3): a randomised, open-label trial. Lancet 2013;381:461-467.
  10. Cortese B, Orrego PS, Agostoni P, et al. Effect of drug-coated balloons in native coronary artery disease left with a dissection. JACC Cardiovasc Interv 2015;8:2003-2009.
  11. Jeger RV, Farah A, Ohlow MA, et al. Drug-coated balloons for small coronary artery disease (BASKET-SMALL 2): an open-label randomised non-inferiority trial. Lancet 2018;392:849-856.
  12. Thygesen K, Alpert JS, Jaffe AS, et al. Third universal definition of myocardial infarction. J Am Coll Cardiol 2012;60:1581-1598.
  13. Schunkert H, Harrell L, Palacios IF. Implications of small reference vessel diameter in patients undergoing percutaneous coronary revascularization. J Am Coll Cardiol 1999;34:40-48.
  14. Moreno R, Fernandez C, Alfonso F, et al. Coronary stenting versus balloon angioplasty in small vessels: a meta-analysis from 11 randomized studies. J Am Coll Cardiol 2004;43:1964-1972.
  15. Scheller B, Vukadinovic D, Jeger R, et al. Survival after coronary revascularization with paclitaxel-coated balloons. J Am Coll Cardiol 2020;75:1017-1028.
  16. Dong P, Mozafari H, Lee J, et al. Mechanical performances of balloon post-dilation for improving stent expansion in calcified coronary artery: computational and experimental investigations. J Mech Behav Biomed Mater 2021;121:104609.
  17. Akiyama T, Moussa I, Reimers B, et al. Angiographic and clinical outcome following coronary stenting of small vessels: a comparison with coronary stenting of large vessels. J Am Coll Cardiol 1998;32:1610-1618.
  18. Cortese B, Bertoletti A. Paclitaxel coated balloons for coronary artery interventions: a comprehensive review of preclinical and clinical data. Int J Cardiol 2012;161:4-12.
  19. Sarno G, Lagerqvist B, Frobert O, et al. Lower risk of stent thrombosis and restenosis with unrestricted use of 'new-generation' drug-eluting stents: a report from the nationwide Swedish Coronary Angiography and Angioplasty Registry (SCAAR). Eur Heart J 2012;33:606-613.
  20. Cortese B, Micheli A, Picchi A, et al. Paclitaxel-coated balloon versus drug-eluting stent during PCI of small coronary vessels, a prospective randomised clinical trial. The PICCOLETO study. Heart 2010;96:1291-1296.
  21. Waksman R, Serra A, Loh JP, et al. Drug-coated balloons for de novo coronary lesions: results from the Valentines II trial. EuroIntervention 2013;9:613-619.
  22. Cutlip DE, Windecker S, Mehran R, et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 2007;115:2344-2351.
  23. Elezi S, Kastrati A, Neumann FJ, Hadamitzky M, Dirschinger J, Schomig A. Vessel size and long-term outcome after coronary stent placement. Circulation 1998;98:1875-1880.
  24. Dorros G, Cowley MJ, Simpson J, et al. Percutaneous transluminal coronary angioplasty: report of complications from the National Heart, Lung, and Blood Institute PTCA Registry. Circulation 1983;67:723-730.
  25. Mehran R, Rao SV, Bhatt DL, et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation 2011;123:2736-2747.
  26. Yu X, Ji F, Xu F, et al. Treatment of large de novo coronary lesions with paclitaxel-coated balloon only: results from a Chinese institute. Clin Res Cardiol 2019;108:234-243.
  27. Kang IS, Shehata I, Shin DH, et al. Comparison between drug-coated balloon angioplasty and second-generation drug-eluting stent placement for the treatment of in-stent restenosis after drug-eluting stent implantation. Heart Vessels 2016;31:1405-1411.
  28. Sim HW, Ananthakrishna R, Chan SP, et al. Treatment of very small de novo coronary artery disease with 2.0 mm drug-coated balloons showed 1-year clinical outcome comparable with 2.0 mm drug-eluting stents. J Invasive Cardiol 2018;30:256-261.
  29. Chaddad R, El-Mokdad R, Lazar L, Cortese B. DCBs as an adjuvant tool to DES for very complex coronary lesions. Rev Cardiovasc Med 2022;23:13.
  30. Silverio A, Buccheri S, Venetsanos D, et al. Percutaneous treatment and outcomes of small coronary vessels: a SCAAR report. JACC Cardiovasc Interv 2020;13:793-804.